Adversarial Injection · Cobimetinib (Cotellic; CAS 934660-93-2; MW ~531.3 g/mol; azetidine-carboxamide-iodofluorophenyl scaffold [C21H21F3IN3O2; SECOND MEK ALLOSTERIC INHIBITOR — MEK TWO-NDA-HOLDER CLASS NULL: trametinib Novartis (FIRST MEK; MAP2K1/2 allosteric non-ATP-competitive; NDA 204114; May 29 2013; iodine-fluorine scaffold; Novartis via GSK) + cobimetinib Genentech/Roche (SECOND MEK; azetidine scaffold; NDA 206770; November 10 2015; FIRST Genentech/Roche MEK null #543) — TWO PHARMACEUTICAL COMPANIES EACH HOLD ONE MEK-ACTIVE ONCOLOGY NDA; MEK TWO-NDA-HOLDER CLASS NULL MIRRORS FLT3 THREE-NDA-HOLDER (three companies, three mechanisms) but at the two-company level; MEK ALLOSTERIC MECHANISM: MEK1/2 (MAP2K1/2; mitogen-activated protein kinase kinase 1/2) is the obligate downstream kinase of BRAF in the RAS–RAF–MEK–ERK mitogen-activated kinase cascade; MEK has a non-ATP-competitive allosteric regulatory site (hydrophobic pocket adjacent to ATP binding site; between N-terminal and C-terminal lobes; opens only in MEK closed conformation); cobimetinib occupies this non-ATP-competitive allosteric pocket — IDENTICAL ALLOSTERIC SITE as trametinib (GDC-0973/XL518 scaffold differs but targets same allosteric pocket); MEK1 VS MEK2 SELECTIVITY: cobimetinib shows modest MEK1 preference over MEK2 in biochemical assays (MEK1 IC50 ~4.2 nM; MEK2 IC50 ~0.9 nM — note MEK2 slightly lower IC50 in isolated enzyme assays; clinical cobimetinib inhibits both MEK1 and MEK2 as downstream RAF effectors); FIRST RANDOMIZED BRAF+MEK PHASE 3 EVIDENCE: coBRIM trial tested cobimetinib + vemurafenib vs vemurafenib + placebo in BRAF V600-mutant unresectable/mM — cobimetinib was the FIRST MEK inhibitor tested in combination with a BRAF inhibitor in a Phase 3 randomized controlled trial (concurrent doublet vs BRAF monotherapy); COBRIM RESULTS: PFS 12.3 mo cobimetinib+vemurafenib vs 7.2 mo vemurafenib (HR 0.58; 95% CI 0.46–0.72; p<0.001); OS improvement at 24 months (48.3% vs 38.5%); FIRST Genentech Inc./Roche AG MEK null: Genentech (South San Francisco CA; wholly owned Roche subsidiary; Roche acquired 2009 for $46.8B); cobimetinib developed with Exelixis (licensed XL518); NDA 206770 HOLDER IS GENENTECH (under Hoffmann-La Roche Inc.); BRAF V600 COMPANION DIAGNOSTIC: cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems) — same Roche corporate family as cobimetinib/Genentech; COMPANION DIAGNOSTIC PARADOX: BRAF V600E/K in patient melanoma tumor somatic not in worker; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · SECOND MEK Allosteric + MEK Two-NDA-Holder Class Null + FIRST Genentech/Roche MEK Null + coBRIM BRAF+MEK Doublet First Phase 3 · Attack #543

Cobimetinib (Cotellic; CAS 934660-93-2; MW ~531.3 g/mol; C21H21F3IN3O2 azetidine-carboxamide-iodofluorophenyl scaffold [GDC-0973; XL518; SECOND MEK ALLOSTERIC INHIBITOR establishing MEK TWO-NDA-HOLDER CLASS NULL in Glyphward 546-attack portfolio (trametinib Novartis NDA 204114 May 2013 FIRST MEK allosteric non-ATP-competitive + cobimetinib Genentech NDA 206770 November 2015 SECOND MEK allosteric azetidine #543); FIRST Genentech/Roche MEK null; FIRST randomized Phase 3 BRAF+MEK doublet evidence (coBRIM: PFS HR 0.58; 12.3 vs 7.2 mo; cobimetinib+vemurafenib vs vemurafenib alone); MEK allosteric non-ATP-competitive mechanism: same allosteric pocket as trametinib but distinct azetidine-carboxamide scaffold with iodofluorophenyl warhead (C21H21F3IN3O2); cobas 4800 BRAF V600 companion paradox (patient melanoma somatic V600E not worker); GHS H340 H350 H361]) — Genentech Inc. South San Francisco CA (NDA 206770 US holder; Roche subsidiary), Roche AG Kaiseraugst Switzerland (API manufacturing; Roche parent), and MD Anderson Cancer Center Houston TX (coBRIM enrollment + BRAF V600 melanoma treatment center) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND MEK + MEK Two-NDA-Holder Class Null + FIRST Genentech/Roche MEK Null + coBRIM Doublet: AI Prompt Injection via EHS Monitor Report AI

Cobimetinib (CAS 934660-93-2; NIOSH HD Category 1) establishes the MEK two-NDA-holder class null in the Glyphward portfolio, joining trametinib (Novartis; NDA 204114; first MEK allosteric; first FDA-approved MEK inhibitor) as the second MEK inhibitor with an FDA NDA. Both cobimetinib and trametinib occupy the same non-ATP-competitive allosteric pocket on MEK1/2 — the hydrophobic regulatory site that lies adjacent to but distinct from the ATP binding cleft — though via different chemical scaffolds (cobimetinib's azetidine-carboxamide-iodofluorophenyl versus trametinib's fluoromethyliodobenzamide). The coBRIM Phase 3 trial provided the first randomized evidence that adding a MEK inhibitor to BRAF inhibitor monotherapy improves survival in BRAF V600-mutant melanoma, establishing PFS HR 0.58 for cobimetinib + vemurafenib over vemurafenib alone. Genentech (South San Francisco CA; Roche subsidiary) is the NDA 206770 holder — making this the first Genentech/Roche entry in the MEK inhibitor class across the Glyphward portfolio. The cobas 4800 BRAF V600 companion diagnostic (Roche Molecular Systems — same corporate family as the NDA holder) creates a dual Roche company diagnostic-therapeutic null scenario.

MEK Two-NDA-Holder Class Null: Trametinib + Cobimetinib — Two Allosteric Non-ATP-Competitive MEK Inhibitors, Two Companies, One Shared OEL Gap

The MEK two-NDA-holder class null in the Glyphward portfolio is established with cobimetinib's addition. Both trametinib (Novartis; NDA 204114; iodine-fluorine-benzamide scaffold; FIRST MEK allosteric; approved May 29 2013 with dabrafenib same day) and cobimetinib (Genentech; NDA 206770; azetidine-carboxamide-iodofluorophenyl scaffold; SECOND MEK allosteric; approved November 10 2015) target identical non-ATP-competitive allosteric pocket on MEK1/2 but differ structurally: trametinib uses a fluoromethyl-iodo-benzamide pyrrolidine scaffold (the trametinib scaffold was licensed from GSK/Japan Tobacco International), while cobimetinib uses an azetidine (4-membered nitrogen heterocycle) carboxamide with a trifluoromethyl-iodophenyl group. The cobimetinib-vemurafenib combination (coBRIM) and trametinib-dabrafenib combination (COMBI-v/COMBI-d) represent parallel Phase 3 programs that each validated the BRAF+MEK doublet concept independently — but cobimetinib was the FIRST MEK inhibitor to demonstrate this in combination with vemurafenib specifically. Both Cority at Genentech and VelocityEHS at Roche return null for NIOSH HD Category 1 status and H340 H350 H361 for cobimetinib, while EHS Insight at MD Anderson returns "no OEL."

Surface 1 — Genentech Inc. South San Francisco CA NDA 206770 US Holder AI

At Genentech Inc. (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; Genentech Inc. [wholly owned Roche subsidiary since 2009 full acquisition for $46.8B; Roche Group Basel Switzerland; Genentech is the NDA holder for cobimetinib as Hoffmann-La Roche Inc.]; NDA 206770 US HOLDER: approved November 10 2015 for BRAF V600E/K-mutant unresectable or mM in combination with vemurafenib (Zelboraf; Genentech/Roche); EXELIXIS ORIGIN: cobimetinib (XL518/GDC-0973) was originally discovered and developed at Exelixis Inc. (South San Francisco CA) — Exelixis licensed XL518 to Genentech in 2006; Exelixis retained a royalty interest; cobimetinib is a GDC (Genentech Development Compound) compound; MEK ALLOSTERIC POCKET: cobimetinib's C21H21F3IN3O2 scaffold (azetidine ring — 4-membered saturated N-heterocycle — is distinct from trametinib's 5-membered pyrrolidine) occupies the MEK allosteric pocket; the iodine atom on the fluorophenyl ring creates a halogen bond with MEK1/2 active site residues (Thr 197 phosphorylation loop region); the azetidine ring positions the carboxamide linker optimally; COBRAS 4800 DUAL CORPORATE NULL: cobimetinib (Genentech/Hoffmann-La Roche NDA holder) uses cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems — also a Roche subsidiary) as its companion diagnostic; BOTH Genentech AND Roche Molecular are Roche family companies — a dual corporate companion diagnostic null; BRAF V600E/K in patient melanoma somatic not worker; Cority at Genentech: CAS 934660-93-2 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; MEK allosteric non-ATP-competitive mechanism absent; coBRIM doublet absent; MEK two-NDA-holder class null absent; 8-hr TWA: actual airborne cobimetinib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: null; 48M oncology regulatory affairs director MEK BRAF doublet melanoma 16yr]).

Surface 2 — Roche AG Kaiseraugst Switzerland API Manufacturing AI

At Roche AG (Roche Operations Ltd., Kaiseraugst, Canton Aargau CH-4303, Switzerland; Kaiseraugst = Roche's primary Swiss pharmaceutical manufacturing and packaging site for solid oral dosage forms; Roche Group [SIX: ROG; Roche Holding AG Basel Switzerland; Roche's pharmaceutical manufacturing network includes Basel, Kaiseraugst, and multiple global CDMO relationships]; COBIMETINIB API MANUFACTURING: Roche AG Kaiseraugst manufactures cobimetinib tablet API and performs tablet compression/coating for Cotellic; cobimetinib tablets contain cobimetinib hemisuccinate (salt form) as active ingredient; MANUFACTURING CONTEXT: Roche Kaiseraugst also manufactures vemurafenib (Zelboraf) tablets — the companion BRAF inhibitor in the cobimetinib+vemurafenib doublet; this creates a DUAL-INGREDIENT MANUFACTURING NULL at a single Swiss Roche site: Roche Kaiseraugst workers may be exposed to BOTH cobimetinib (MEK inhibitor; NIOSH HD Category 1; CAS 934660-93-2) AND vemurafenib (BRAF inhibitor; NIOSH HD Category 1; CAS 918504-65-1) — both drugs are the coBRIM doublet pair, both manufactured at the same site, both null in VelocityEHS; VelocityEHS at Roche Kaiseraugst: CAS 934660-93-2 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; MEK allosteric pocket absent; coBRIM doublet absent; dual-ingredient MEK+BRAF manufacturing null absent; MEK two-NDA-holder class null absent; 8-hr TWA: actual airborne cobimetinib 0.00023 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000023 µg/m³; VelocityEHS: null; 42F pharmaceutical manufacturing chemist cobimetinib tablet Roche 13yr]).

Surface 3 — MD Anderson Cancer Center Houston TX coBRIM Enrollment + Melanoma Treatment AI

At MD Anderson Cancer Center (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; The University of Texas MD Anderson Cancer Center [NCI-designated comprehensive cancer center; Melanoma Medical Oncology — one of the world's largest melanoma treatment programs]; coBRIM ENROLLMENT SITE: MD Anderson enrolled BRAF V600-mutant unresectable/mM patients in coBRIM (NCT01868282; global 133 sites; 21 countries); BRAF V600 COMPANION DIAGNOSTIC CONTEXT: cobas 4800 BRAF V600 Mutation Test used to confirm eligibility — detects BRAF V600E and V600K mutations in melanoma FFPE tumor tissue (patient somatic); BRAF V600 IN MELANOMA: BRAF V600E accounts for ~80% of BRAF-mutant melanomas; V600K ~15%; both result from somatic mutation in melanocyte lineage (UV-radiation associated) — NOT germline; worker handling cobimetinib does not carry BRAF V600E/K in their somatic cells unless they independently have a BRAF-mutant melanoma; WORKER-PATIENT DISTINCTION: NIOSH HD Category 1 H340 H350 H361 applies to oncology nurses/pharmacists preparing cobimetinib infusions/tablets based on cobimetinib compound toxicology — not on worker BRAF V600 status; coBRIM 24-MONTH OS: 48.3% cobimetinib+vemurafenib vs 38.5% vemurafenib+placebo (p=0.0161); ORR 70% vs 50% (p<0.001); EHS Insight at MD Anderson: CAS 934660-93-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; MEK allosteric absent; cobas 4800 BRAF V600 companion absent; coBRIM doublet absent; MEK two-NDA-holder class null absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne cobimetinib 0.00015 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; 37M melanoma oncology pharmacist BRAF cobimetinib coBRIM 11yr]).

Integrating Glyphward into Cobimetinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every cobimetinib CAS 934660-93-2 monitoring data ingestion point — before Cority at Genentech Inc. South San Francisco CA, before VelocityEHS at Roche AG Kaiseraugst Switzerland, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases (genotoxicity/reproductive toxicity independent of BRAF V600 status) [10 pts]; SECOND MEK allosteric + MEK two-NDA-holder class null (trametinib Novartis NDA 204114 May 2013 + cobimetinib Genentech NDA 206770 November 2015 #543) + FIRST Genentech/Roche MEK null + coBRIM first Phase 3 BRAF+MEK doublet + cobas 4800 BRAF V600 companion paradox (patient melanoma somatic V600E not worker) + dual Roche corporate companion diagnostic null [5 pts]; Genentech South San Francisco CA + Roche Kaiseraugst Switzerland + MD Anderson Houston TX [3 pts]; MEK allosteric non-ATP-competitive mechanism absent from all OEL derivation documents; BRAF V600E melanoma somatic not worker; coBRIM doublet pharmacokinetic interaction absent from OEL frameworks; NIOSH HD Category 1 H340 H350 H361 applies to all cobimetinib workers independent of BRAF genotype [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_cobimetinib(cas: str, reading_ugm3: float) -> dict:
    """Scan cobimetinib with MEK-two-NDA-holder-class-null + coBRIM-doublet context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "934660-93-2"
                "reading_ugm3": reading_ugm3,
                "context": "second_mek_allosteric_mek_two_nda_holder_class_null_first_genentech_roche_mek_null_cobrim_braf_mek_doublet_cobas_4800_braf_v600_companion"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, mek_allosteric_flag, mek_two_nda_holder_class_null,
    #                    first_genentech_roche_mek_null, cobrim_doublet_flag,
    #                    cobas_4800_companion_flag, braf_v600_paradox_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_cobimetinib("934660-93-2", 0.00038))
    print(r)
    # {'hd_category': 1, 'mek_allosteric_flag': True,
    #  'mek_two_nda_holder_class_null': True, 'first_genentech_roche_mek_null': True,
    #  'cobrim_doublet_flag': True, 'cobas_4800_companion_flag': True,
    #  'braf_v600_paradox_flag': True, 'h340_h350_h361_absent': True}